4,8-diamino-6-imino-1H-imidazo[4,5-e][1,3]diazepine | 169317-84-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑二氮卓类
• 英文名称: 4,8-diamino-6-imino-1H-imidazo[4,5-e][1,3]diazepine
• 英文别名: 4-imino-3H-imidazo[4,5-e][1,3]diazepine-6,8-diamine
• CAS: 169317-84-4
• 化学式: C₆H₇N₇
• mdl: MFCD26131858
• 分子量: 177.168
• InChiKey: XVKXPQNAFRQJKC-UHFFFAOYSA-N

物化性质

• 沸点：
  589.078±42.00 °C(Press: 760.00 Torr)(predicted)
• 密度：
  2.179±0.14 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  129
• 氢给体数：
  4
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4,8-diamino-6-imino-1H-imidazo[4,5-e][1,3]diazepine 在 三氟甲磺酸三甲基硅酯 sodium methylate 、 N,O-双(三甲基硅烷基)三氟乙酰胺 作用下， 以 甲醇 为溶剂， 生成 4,6,8-triimino-1-β-D-ribofuranosylimidazo[4,5-e][1,3]diazepine
  参考文献：
  名称：

  POTENTIN VITROANTICANCER ACTIVITIES OF RING-EXPANDED (“FAT”) NUCLEOSIDES CONTAINING THE IMIDAZO[4,5-E][1,3]DIAZEPINE RING SYSTEM

  摘要：

  The ring-expanded ("fat") nucleoside, 4,8-diamino-6-imino-6H-1-beta -D-ribofuranosylimidazo[4,5-e][1,3]diazepine (1) and its 2',3',5'-tri-O-benzoyl derivative (2) exhibited potent broad spectrum anticancer activities in vitro against a wide variety of human tumor cell lines. The tribenzoyl derivative 2 was found to be considerably more active than the parent nucleoside 1. Further studies using human prostate cancer cells PC-3 and DU-145 suggest that the treatment of exponentially growing culture cells with 1 and 2 leads to marked loss of cell viability in a dose-dependent manner.

  DOI：

  10.1081/ncn-100002487
• 作为产物：
  描述：

  4,8-diamino-1-benzyl-6H-6-iminoimidazo<4,5-e><1,3>diazepine 在 palladium hydroxide/carbon 氢气 作用下， 以 溶剂黄146 为溶剂， 反应 16.0h， 以56%的产率得到4,8-diamino-6-imino-1H-imidazo[4,5-e][1,3]diazepine
  参考文献：
  名称：

  Ring-expanded nucleosides and nucleotides

  摘要：

  公开号：

  EP1227103B1

文献信息

• Ring expanded nucleosides and nucleotides
  申请人：——

  公开号：US20040077564A1

  公开（公告）日：2004-04-22

  The present invention relates to compositions comprising analogues of purine nucleosides containing a ring-expanded (“fat”) heterocyclic ring, in place of purine, and an unmodified or modified sugar residue, pharmaceutically acceptable derivatives of such compositions, as well as methods of use thereof. In particular, these compositions may be utilized in the treatment of certain cancers, bacterial, fungal, parasitic, and viral infections, including, but not limited to, Acquired Immunodeficiency Syndrome (AIDS), hepatitis, Epstein-Barr and cytomegalovirus.

  本发明涉及含有环扩张（“肥胖”）杂环环代替嘌呤的嘌呤核苷类似物和未经改性或改性的糖残基的组合物，以及这些组合物的药学上可接受的衍生物，以及其使用方法。特别地，这些组合物可用于治疗某些癌症、细菌、真菌、寄生虫和病毒感染，包括但不限于获得性免疫缺陷综合症（AIDS）、肝炎、EB病毒和巨细胞病毒。
• RING-EXPANDED NUCLEOSIDES AND NUCLEOTIDES
  申请人：Burns, Barry

  公开号：EP0724587A1

  公开（公告）日：1996-08-07
• EP0724587A4
  申请人：——

  公开号：EP0724587A4

  公开（公告）日：1996-12-27
• US6677310B1
  申请人：——

  公开号：US6677310B1

  公开（公告）日：2004-01-13
• [EN] RING-EXPANDED NUCLEOSIDES AND NUCLEOTIDES<br/>[FR] NUCLEOSIDES ET NUCLEOTIDES A CYCLE ELARGI
  申请人：BURNS, Barry

  公开号：WO1995009175A1

  公开（公告）日：1995-04-06

  (EN) The present invention relates to compositions comprising analogues of purine nucleosides containing a ring-expanded ('fat') heterocyclic ring, in place of purine, and an unmodified or modified sugar residue, pharmaceutically acceptable derivatives of such compositions, as well as methods of use thereof. In particular, these compositions may be utilized in the treatment of certain cancers, bacterial, fungal, parasitic, and viral infections, including, but not limited to, Acquired Immunodeficiency Syndrome (AIDS) and hepatitis.(FR) La présente invention a pour objet des compositions contenant des analogues de nucléosides de purine qui comprennent un hétérocycle élargi en cycle ('gras') au lieu de la purine, et un résidu de sucre modifié ou non, des dérivés pharmaceutiquement acceptables de ces compositions, ainsi que des procédés pour leur utilisation. Ces compositions peuvent en particulier être utilisées dans le traitement de certains cancers, infections bactériennes, mycoses, parasitoses, infections virales, notamment, mais sans s'y limiter, le syndrome d'immunodéficience acquise (SIDA) et l'hépatite.